InvestorsHub Logo
Followers 38
Posts 2912
Boards Moderated 0
Alias Born 06/05/2012

Re: biotech2010 post# 3331

Tuesday, 06/12/2018 10:02:25 AM

Tuesday, June 12, 2018 10:02:25 AM

Post# of 3839
Agreed. GALT’s shareholders would be so much better off today if Traber had left several years ago.

“Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold H. Shlevin, Ph.D., currently the Company’s Chief Operating Officer (COO), has been appointed Chief Executive Officer (CEO) and President to succeed Peter G. Traber, M.D., who has tendered his resignation as President, CEO and Chief Medical Officer. The transition will be effective July 6, 2018.” - GALT PR

"It is difficult to get a man to understand something, when his salary depends upon his not understanding it."

Upton Sinclair

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GALT News